[Influence of molecular pathology on oncological surgery of liver and bile duct tumors].

Background: Molecular pathology is increasingly being used to guide treatment in oncology. Approximately 25% of all hepatocellular carcinomas (HCC) and 50% of cholangiocarcinomas (CCA) present with known cancer-relevant mutations; however, the impact of the mutations on the treatment of these tumors is not yet sufficiently understood.

Purpose: To evaluate the current literature on molecular pathological advances in HCC/CCA and the potential impact on oncological surgery.